Longitudinal, computer assisted analysis in IPF
IPF 的纵向计算机辅助分析
基本信息
- 批准号:7897726
- 负责人:
- 金额:$ 38.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-08-01 至 2012-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcetylcysteineAgreementAncillary StudyAwardAzathioprineCessation of lifeClinical TrialsComputer AssistedDataData AnalysesData CollectionDatabasesDiagnosisDiseaseEnrollmentEtiologyFibrosisFutureGlassHamman-Rich syndromeHigh Resolution Computed TomographyHoneycomb PatternLungManuscriptsMeasurableMeasuresMethodologyMethodsOutcome MeasureParentsPatientsPatternPhysiciansPhysiologyPlacebosPlayPrednisonePreparationProtocols documentationQuality of lifeRadiology SpecialtyRandomizedResearchResearch PersonnelResourcesRespiratory physiologyRiskRoleScanningStructure of parenchyma of lungSurrogate EndpointSystemTestingTextureTherapeutic AgentsTimeTimeLineTrainingVital capacityWorkabstractingarmbasecomputerizedcostdisabilitydouble-blind placebo controlled triallongitudinal analysismortalitynovelnovel therapeuticsoutcome forecastprospectivepulmonary functionradiologistresponse
项目摘要
DESCRIPTION (provided by applicant):
Idiopathic pulmonary fibrosis (IPF), the most common idiopathic interstitial pneumonia, is characterized by progressive fibrosis leading to increased disability and death. There is no cure for IPF. Mortality is the most important and easily definable endpoint for clinical trials of novel therapeutic agents. Unfortunately the size, duration, and cost of mortality-powered trials are prohibitive. This fact has led investigators to actively pursue identification of easily-measurable surrogate endpoints that predict future mortality. We demonstrated that six and 12 month decline in forced vital capacity (FVC) is associated with an increased risk of subsequent mortality. Unfortunately decline in physiology is unable to correctly predict mortality in all patients as many patients die acutely prior to demonstrating a decline in FVC while others can survive for extended periods of time despite large losses of lung function. These data highlight the need for novel surrogate endpoints that can be used to efficiently evaluate therapeutic agents for patients with IPF. High resolution computed tomography (HRCT) plays a pivotal role in the diagnosis of IPF. Baseline qualitative and semi- quantitative scoring of HRCT features consistently predicts long-term prognosis; longitudinal change has been studied less consistently. Difficulties in utilizing semi-quantitative HRCT scoring systems include physician time, inter-rater disagreement, and the rather large changes required to impact semi-quantitative scores. The Adaptive Multiple Feature Method (AMFM) is a computerized texture-based method for characterizing lung HRCT features. The overall hypothesis of this application is that the computer aided AMFM can be trained to recognize 3D features of IPF (honeycomb pattern, ground glass opacity). Furthermore, quantitative scoring by the AMFM will have better correlation with longitudinal change in forced vital capacity (FVC) & mortality compared to semi-quantitative methodology. This study will utilize cases from the Lung Tissue Research Consortium and the IPF network (IPFnet) to obtain a diverse group of patients with IPF for training the AMFM. Longitudinal aims will utilize the IPFnet's multi-center, randomized, double-blind placebo controlled trial of prednisone + azathioprine + N-acetylcysteine or N-acetylcysteine alone versus placebo in IPF patients (PANTHER study). PANTHER will enroll 130 patients, followed for 60 weeks, into each treatment arm beginning March, 2008. This application will provide a mechanism for obtaining longitudinal HRCT scans which are not part of the PANTHER protocol. This application will take advantage of the IPFnet to develop a HRCT database with baseline and longitudinal data. Through this award we will 1) test if computer aided analysis can recognize and quantify HRCT features of IPF 2) compare the agreement of semi- quantitative (radiologist) and quantitative (AMFM) measures of baseline and longitudinal changes in HRCT features 3) evaluate if longitudinal changes in HRCT can function as surrogate endpoints in clinical trials through correlations with changes in pulmonary function, quality of life, and mortality. Statement of Relevance: Idiopathic pulmonary fibrosis is an incurable disease of unknown etiology characterized by progressive fibrosis of the lung parenchyma leading to increased disability and eventual death. The study of novel agents to impact this disease is critical to access for potential impact on quantity and quality of life. Unfortunately the size, duration, and cost of mortality-powered trials are prohibitive. This study will evaluate if computer aided analysis of longitudinal changes in high resolution computed tomography scans correlates with changes in physiology, quality of life, and survival in patients with IPF. If true, changes in high resolution computed tomography could serve as a non-invasive surrogate endpoint in the study of novel agents to treat this devastating disease. (End of Abstract)
描述(由申请人提供):
特发性肺纤维化(IPF)是最常见的特发性间质性肺炎,其特征是进行性纤维化,导致残疾和死亡增加。IPF无法治愈。死亡率是新型治疗药物临床试验中最重要且最容易确定的终点。不幸的是,死亡率试验的规模、持续时间和成本都令人望而却步。这一事实促使研究人员积极寻找易于测量的替代终点来预测未来的死亡率。我们证明了6个月和12个月用力肺活量(FVC)下降与随后死亡风险增加相关。不幸的是,生理学下降无法正确预测所有患者的死亡率,因为许多患者在FVC下降之前急性死亡,而其他患者尽管肺功能大量丧失,但仍能存活较长时间。这些数据突出表明需要新的替代终点,可用于有效评价IPF患者的治疗药物。高分辨率计算机断层扫描(HRCT)在IPF的诊断中起着关键作用。HRCT特征的基线定性和半定量评分一致地预测长期预后;纵向变化的研究不太一致。使用半定量HRCT评分系统的困难包括医生时间、评分者之间的分歧以及影响半定量评分所需的相当大的变化。自适应多特征方法(AMFM)是一种基于纹理的计算机化方法,用于表征肺部HRCT特征。本申请的总体假设是,计算机辅助AMFM可以被训练以识别IPF的3D特征(蜂窝状图案、毛玻璃不透明度)。此外,与半定量方法相比,AMFM的定量评分与用力肺活量(FVC)和死亡率的纵向变化具有更好的相关性。本研究将利用来自肺组织研究联盟和IPF网络(IPFnet)的病例,以获得不同的IPF患者组,用于培训AMFM。纵向目标将利用IPFnet的多中心、随机、双盲安慰剂对照试验,在IPF患者中比较泼尼松+硫唑嘌呤+N-乙酰半胱氨酸或N-乙酰半胱氨酸单药治疗与安慰剂治疗(PANTHER研究)。从2008年3月开始,PANTHER将招募130名患者进入每个治疗组,随访60周。该应用程序将提供一种机制,用于获得纵向HRCT扫描,这不是PANTHER方案的一部分。该应用程序将利用IPFnet开发包含基线和纵向数据的HRCT数据库。通过该奖项,我们将1)测试计算机辅助分析是否可以识别和量化IPF的HRCT特征,2)比较半定量分析的一致性,HRCT特征的基线和纵向变化的(放射科医生)和定量(AMFM)测量3)通过与肺功能、生活质量、and mortality.相关性声明:特发性肺纤维化是一种病因不明的不治之症,其特征在于肺实质的进行性纤维化,导致残疾增加和最终死亡。研究影响这种疾病的新药物对于获得对生活数量和质量的潜在影响至关重要。不幸的是,死亡率试验的规模、持续时间和成本都令人望而却步。本研究将评价高分辨率计算机断层扫描纵向变化的计算机辅助分析是否与IPF患者的生理学、生活质量和生存期变化相关。如果是真的,高分辨率计算机断层扫描的变化可以作为治疗这种毁灭性疾病的新药物研究的非侵入性替代终点。(End摘要)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KEVIN R FLAHERTY其他文献
RACE-SPECIFIC REFERENCE VALUES IMPEDE ACCESS TO CARE FOR BLACK AND HISPANIC PATIENTS WITH PULMONARY FIBROSIS
- DOI:
10.1016/j.chest.2023.07.2040 - 发表时间:
2023-10-01 - 期刊:
- 影响因子:
- 作者:
AYODEJI ADEGUNSOYE;WENDI R MASON BACHMAN;KEVIN R FLAHERTY;ZHONGZE LI;SACHIN GUPTA - 通讯作者:
SACHIN GUPTA
ASSOCIATIONS OF PLASMA OMEGA-3 FATTY ACIDS WITH PROGRESSION AND SURVIVAL IN PULMONARY FIBROSIS
- DOI:
10.1016/j.chest.2023.07.1998 - 发表时间:
2023-10-01 - 期刊:
- 影响因子:
- 作者:
JOHN KIM;SHWU-FAN MA;JENNIE MA;YONG HUANG;CATHERINE BONHAM;JUSTIN OLDHAM;AYODEJI ADEGUNSOYE;MARY E STREK;KEVIN R FLAHERTY;EMMA STRICKLAND;JOSHUA J MOONEY;SHRESTHA GHOSH;LAURIE GLIMCHER;KRISHNA RAO MADDIPATI;IMRE NOTH - 通讯作者:
IMRE NOTH
KEVIN R FLAHERTY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KEVIN R FLAHERTY', 18)}}的其他基金
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型研究的前瞻性治疗效果
- 批准号:
10596595 - 财政年份:2019
- 资助金额:
$ 38.45万 - 项目类别:
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型研究的前瞻性治疗效果
- 批准号:
10385682 - 财政年份:2019
- 资助金额:
$ 38.45万 - 项目类别:
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型研究的前瞻性治疗效果
- 批准号:
10021690 - 财政年份:2019
- 资助金额:
$ 38.45万 - 项目类别:
Forging a road to personalized medicine in interstitial lung diseases
开辟间质性肺疾病个体化医疗之路
- 批准号:
8656765 - 财政年份:2012
- 资助金额:
$ 38.45万 - 项目类别:
Forging a road to personalized medicine in interstitial lung diseases
开辟间质性肺疾病个体化医疗之路
- 批准号:
8462680 - 财政年份:2012
- 资助金额:
$ 38.45万 - 项目类别:
Forging a road to personalized medicine in interstitial lung diseases
开辟间质性肺疾病个体化医疗之路
- 批准号:
8224611 - 财政年份:2012
- 资助金额:
$ 38.45万 - 项目类别:
Forging a road to personalized medicine in interstitial lung diseases
开辟间质性肺疾病个体化医疗之路
- 批准号:
9187992 - 财政年份:2012
- 资助金额:
$ 38.45万 - 项目类别:
CTRIP: Molecular phenotypes of rapidly progressive idiopathic pulmonary fibrosis
CTRIP:快速进展性特发性肺纤维化的分子表型
- 批准号:
7939866 - 财政年份:2009
- 资助金额:
$ 38.45万 - 项目类别:
CTRIP: Molecular phenotypes of rapidly progressive idiopathic pulmonary fibrosis
CTRIP:快速进展性特发性肺纤维化的分子表型
- 批准号:
7857151 - 财政年份:2009
- 资助金额:
$ 38.45万 - 项目类别:
Longitudinal, computer assisted analysis in IPF
IPF 的纵向计算机辅助分析
- 批准号:
8117529 - 财政年份:2008
- 资助金额:
$ 38.45万 - 项目类别:
相似海外基金
A study for cross borders Indonesian nurses and care workers: Case of Japan-Indonesia Economic Partnership Agreement
针对跨境印度尼西亚护士和护理人员的研究:日本-印度尼西亚经济伙伴关系协定的案例
- 批准号:
22KJ0334 - 财政年份:2023
- 资助金额:
$ 38.45万 - 项目类别:
Grant-in-Aid for JSPS Fellows
NSF-NOAA Interagency Agreement (IAA) for the Global Oscillations Network Group (GONG)
NSF-NOAA 全球振荡网络组 (GONG) 机构间协议 (IAA)
- 批准号:
2410236 - 财政年份:2023
- 资助金额:
$ 38.45万 - 项目类别:
Cooperative Agreement
Conditions for U.S. Agreement on the Closure of Contested Overseas Bases: Relations of Threat, Alliance and Base Alternatives
美国关于关闭有争议的海外基地协议的条件:威胁、联盟和基地替代方案的关系
- 批准号:
23K18762 - 财政年份:2023
- 资助金额:
$ 38.45万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
MSI Smart Manufacturing Data Hub – Open Calls Grant Funding Agreement
MSI 智能制造数据中心 – 公开征集赠款资助协议
- 批准号:
900240 - 财政年份:2023
- 资助金额:
$ 38.45万 - 项目类别:
Collaborative R&D
Challenges of the Paris Agreement Exposed by the Energy Shift by External Factors: The Case of Renewable Energy Policies in Japan, the U.S., and the EU
外部因素导致的能源转移对《巴黎协定》的挑战:以日本、美国和欧盟的可再生能源政策为例
- 批准号:
23H00770 - 财政年份:2023
- 资助金额:
$ 38.45万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Continuation of Cooperative Agreement between U.S. Food and Drug Administration and S.C. Department of Health and Environmental Control (DHEC) for MFRPS Maintenance.
美国食品和药物管理局与南卡罗来纳州健康与环境控制部 (DHEC) 继续签订 MFRPS 维护合作协议。
- 批准号:
10829529 - 财政年份:2023
- 资助金额:
$ 38.45万 - 项目类别:
National Ecological Observatory Network Governing Cooperative Agreement
国家生态观测站网络治理合作协议
- 批准号:
2346114 - 财政年份:2023
- 资助金额:
$ 38.45万 - 项目类别:
Cooperative Agreement
The Kansas Department of Agriculture's Flexible Funding Model Cooperative Agreement for MFRPS Maintenance, FPTF, and Special Project.
堪萨斯州农业部针对 MFRPS 维护、FPTF 和特别项目的灵活资助模式合作协议。
- 批准号:
10828588 - 财政年份:2023
- 资助金额:
$ 38.45万 - 项目类别:
Robust approaches for the analysis of agreement between clinical measurements: development of guidance and software tools for researchers
分析临床测量之间一致性的稳健方法:为研究人员开发指南和软件工具
- 批准号:
MR/X029301/1 - 财政年份:2023
- 资助金额:
$ 38.45万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Linguistic transfer in a contact variety of Spanish: Gender agreement production and attitudes
博士论文研究:西班牙语接触变体中的语言迁移:性别协议的产生和态度
- 批准号:
2234506 - 财政年份:2023
- 资助金额:
$ 38.45万 - 项目类别:
Standard Grant